Philippe Wolgen

Dr Wolgen joined the CLINUVEL board in 2005 and brings his finance experience and professional contacts in European capital markets to the Company. As a former equity analyst, his in-depth analysis and expertise of the life science sector has been an asset to CLINUVEL. Previously, he held positions in private pharmaceutical companies in Europe, as MD of two medical centres in the UK and Israel, and consulted medical device companies. He has been instrumental in raising A$95 million since 2006 for the funding of the current development program of SCENESSE® (afamelanotide 16mg).

Dr Wolgen holds an MBA from Columbia University NY and the London Business School and an MD from the University of Utrecht, the Netherlands.